top of page
>
>
Indication evaluation and prioritization for development stage pharmaceutical client
Client Problems
- A privately-held, development stage pharmaceutical company wanted to understand the clinical and commercial factors across a breadth of indications in order to prioritize development
- There were initial thoughts on several broad disease areas, but no concrete goal or therapeutic target
What We Did
- Started with a narrow selection of indication in the first round of study, and then expanded into a total of 12 indications (grouped into three broad categories) to assess the full potential breadth of the market
Our Results And Insight
- Indications were evaluated along commercial, technical, and clinical dimensions.
- Within these dimensions, scores were assigned across 14 sub-categories, and summed to represent total opportunity
- Based on these scores and other factors, indications were ranked from highest to lowest opportunity
See other case studies
Commercial Strategy case studies >
Portfolio Management case studies >
Gene Therapy & Orphan Disease case studies >
Service Areas Details
Commercial Strategy (Indication Prioritization)
Therapeutic Areas Details
Gene Therapy & Orphan Disease
Featured Consultants
bottom of page